{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,4]],"date-time":"2026-10-04T10:49:35Z","timestamp":1791110975635,"version":"4.1.0"},"reference-count":55,"publisher":"Impact Journals, LLC","issue":"15","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Oncotarget"],"published-print":{"date-parts":[[2016,4,12]]},"DOI":"10.18632\/oncotarget.7195","type":"journal-article","created":{"date-parts":[[2016,2,5]],"date-time":"2016-02-05T07:31:41Z","timestamp":1454657501000},"page":"19559-19574","source":"Crossref","is-referenced-by-count":20,"title":["Synergistic antitumor activity of histone deacetylase inhibitors and anti-ErbB3 antibody in NSCLC primary cultures via modulation of ErbB receptors expression"],"prefix":"10.18632","volume":"7","author":[{"given":"Chiara","family":"Ciardiello","sequence":"first","affiliation":[{"name":"Experimental Pharmacology Unit, Istituto Nazionale Tumori Fondazione G. Pascale - IRCCS, 80131 Naples, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria Serena","family":"Roca","sequence":"additional","affiliation":[{"name":"Experimental Pharmacology Unit, Istituto Nazionale Tumori Fondazione G. Pascale - IRCCS, 80131 Naples, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessia","family":"Noto","sequence":"additional","affiliation":[{"name":"Experimental Pharmacology Unit, Istituto Nazionale Tumori Fondazione G. Pascale - IRCCS, 80131 Naples, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesca","family":"Bruzzese","sequence":"additional","affiliation":[{"name":"Experimental Pharmacology Unit, Istituto Nazionale Tumori Fondazione G. Pascale - IRCCS, 80131 Naples, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tania","family":"Moccia","sequence":"additional","affiliation":[{"name":"Experimental Pharmacology Unit, Istituto Nazionale Tumori Fondazione G. Pascale - IRCCS, 80131 Naples, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carlo","family":"Vitagliano","sequence":"additional","affiliation":[{"name":"Experimental Pharmacology Unit, Istituto Nazionale Tumori Fondazione G. Pascale - IRCCS, 80131 Naples, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elena Di","family":"Gennaro","sequence":"additional","affiliation":[{"name":"Experimental Pharmacology Unit, Istituto Nazionale Tumori Fondazione G. Pascale - IRCCS, 80131 Naples, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gennaro","family":"Ciliberto","sequence":"additional","affiliation":[{"name":"Scientific Direction, Istituto Nazionale Tumori Fondazione G. Pascale - IRCCS, 80131 Naples, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giuseppe","family":"Roscilli","sequence":"additional","affiliation":[{"name":"Takis s.r.l., University, 00161 Rome, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luigi","family":"Aurisicchio","sequence":"additional","affiliation":[{"name":"Takis s.r.l., University, 00161 Rome, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emanuele","family":"Marra","sequence":"additional","affiliation":[{"name":"Takis s.r.l., University, 00161 Rome, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rita","family":"Mancini","sequence":"additional","affiliation":[{"name":"Department of Surgery \u201cP.Valdoni\u201d and Department of Clinical and Molecular Medicine, \u201cLa Sapienza\u201d University, 00161 Rome, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alfredo","family":"Budillon","sequence":"additional","affiliation":[{"name":"Experimental Pharmacology Unit, Istituto Nazionale Tumori Fondazione G. Pascale - IRCCS, 80131 Naples, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessandra","family":"Leone","sequence":"additional","affiliation":[{"name":"Experimental Pharmacology Unit, Istituto Nazionale Tumori Fondazione G. Pascale - IRCCS, 80131 Naples, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"7892","published-online":{"date-parts":[[2016,2,4]]},"reference":[{"key":"1","first-page":"261","article-title":"Targeting the epigenome in lung cancer: expanding approaches to epigenetic therapy","volume":"3","author":"Bates","year":"2013","journal-title":"Front Oncol"},{"key":"2","doi-asserted-by":"crossref","first-page":"e73","DOI":"10.1371\/journal.pmed.0020073","article-title":"Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domain","volume":"2","author":"Varmus","year":"2005","journal-title":"PLoS Med"},{"key":"3","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1038\/nrclinonc.2010.64","article-title":"Targeted therapy in non-small-cell lung cancer\u2014is it becoming a reality?","volume":"7","author":"Kurzrock","year":"2010","journal-title":"Nat Rev Clin Oncol"},{"key":"4","doi-asserted-by":"crossref","first-page":"4829","DOI":"10.1158\/1078-0432.CCR-08-2921","article-title":"HER family receptor abnormalities in lung cancer brain metastases and corresponding primary tumors","volume":"15","author":"Wistuba","year":"2009","journal-title":"Clin Cancer Res"},{"key":"5","first-page":"142","article-title":"High c-erbB-3 protein expression is associated with shorter survival in advanced non-small cell lung carcinomas","volume":"10","author":"Cagle","year":"1997","journal-title":"Mod Pathol"},{"key":"6","doi-asserted-by":"crossref","first-page":"4372s","DOI":"10.1158\/1078-0432.CCR-06-0795","article-title":"The role of the ErbB family members in non-small cell lung cancers sensitive to epidermal growth factor receptor kinase inhibitors","volume":"12","author":"Cantley","year":"2006","journal-title":"Clin Cancer Res"},{"key":"7","doi-asserted-by":"publisher","first-page":"24823","DOI":"10.18632\/oncotarget.4485","article-title":"Combination of antibodies directed against different ErbB3 surface epitopes prevents the establishment of resistance to BRAF\/MEK inhibitors in melanoma","volume":"6","author":"Torrisi","year":"2015","journal-title":"Oncotarget"},{"key":"8","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1186\/1479-5876-11-180","article-title":"Activation of an early feedback survival loop involving phospho-ErbB3 is a general response of melanoma cells to RAF\/MEK inhibition and is abrogated by anti-ErbB3 antibodies","volume":"11","author":"Ciliberto","year":"2013","journal-title":"J Transl Med"},{"key":"9","first-page":"3381","article-title":"Novel anti-ErbB3 monoclonal antibodies show therapeutic efficacy in xenografted and spontaneous mouse tumors","volume":"227","author":"Ciliberto","year":"2013","journal-title":"J Cell Physiol"},{"key":"10","doi-asserted-by":"crossref","first-page":"1455","DOI":"10.4161\/cc.19861","article-title":"Monoclonal antibody-induced ErbB3 receptor internalization and degradation inhibits growth and migration of human melanoma cells","volume":"11","author":"Ciliberto","year":"2012","journal-title":"Cell Cycle"},{"key":"11","doi-asserted-by":"publisher","first-page":"1253","DOI":"10.18632\/oncotarget.1141","article-title":"Combination therapy with anti-ErbB3 monoclonal antibodies and EGFR TKIs potently inhibits non-small cell lung cancer","volume":"4","author":"Aurisicchio","year":"2013","journal-title":"Oncotarget"},{"key":"12","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1097\/JTO.0b013e318194fae7","article-title":"Histone deacetylase inhibitor romidepsin enhances anti-tumor effect of erlotinib in non-small cell lung cancer (NSCLC) cell lines","volume":"4","author":"Frenkel","year":"2009","journal-title":"J Thorac Oncol"},{"key":"13","article-title":"Histone deacetylase inhibitor (HDACI) mechanisms of action: Emerging insights","author":"Grant","year":"2014","journal-title":"Pharmacol Ther"},{"key":"14","doi-asserted-by":"crossref","first-page":"119","DOI":"10.2174\/157489207780832450","article-title":"Histone deacetylase inhibitors: a new wave of molecular targeted anticancer agents","volume":"2","author":"Caraglia","year":"2007","journal-title":"Recent Pat Anticancer Drug Discov"},{"key":"15","first-page":"435","article-title":"Acetylation of proteins as novel target for antitumor therapy: review article","volume":"26","author":"Budillon","year":"2004","journal-title":"Amino Acids"},{"key":"16","doi-asserted-by":"crossref","first-page":"2378","DOI":"10.1002\/jcp.22574","article-title":"HDAC inhibitor vorinostat enhances the antitumor effect of gefitinib in squamous cell carcinoma of head and neck by modulating ErbB receptor expression and reverting EMT","volume":"226","author":"Budillon","year":"2011","journal-title":"J Cell Physiol"},{"key":"17","doi-asserted-by":"crossref","first-page":"e878","DOI":"10.1038\/cddis.2013.406","article-title":"Panobinostat synergizes with zoledronic acid in prostate cancer and multiple myeloma models by increasing ROS and modulating mevalonate and p38-MAPK pathways","volume":"4","author":"Caraglia","year":"2013","journal-title":"Cell Death Dis"},{"key":"18","doi-asserted-by":"crossref","first-page":"3075","DOI":"10.1158\/1535-7163.MCT-09-0254","article-title":"Synergistic antitumor effect between vorinostat and topotecan in small cell lung cancer cells is mediated by generation of reactive oxygen species and DNA damage-induced apoptosis","volume":"8","author":"Budillon","year":"2009","journal-title":"Mol Cancer Ther"},{"key":"19","doi-asserted-by":"crossref","first-page":"1680","DOI":"10.1038\/sj.bjc.6605969","article-title":"Vorinostat synergises with capecitabine through upregulation of thymidine phosphorylase","volume":"103","author":"Budillon","year":"2010","journal-title":"Br J Cancer"},{"key":"20","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1016\/j.freeradbiomed.2015.07.155","article-title":"Vorinostat synergizes with EGFR inhibitors in NSCLC cells by increasing ROS via up-regulation of the major mitochondrial porin VDAC1 and modulation of the c-Myc-NRF2-KEAP1 pathway","volume":"89","author":"Budillon","year":"2015","journal-title":"Free radical biology & medicine"},{"key":"21","first-page":"2010","article-title":"Molecular and therapeutic potential and toxicity of valproic acid","author":"Diederich","year":"2010","journal-title":"J Biomed Biotechnol"},{"key":"22","doi-asserted-by":"publisher","first-page":"7715","DOI":"10.18632\/oncotarget.6802","article-title":"Valproic acid potentiates the anticancer activity of capecitabineandin breast cancer models via induction of thymidine phosphorylase expression","volume":"7","author":"Di Gennaro","year":"2016","journal-title":"Oncotarget"},{"key":"23","doi-asserted-by":"crossref","first-page":"e21320","DOI":"10.1371\/journal.pone.0021320","article-title":"Spheres derived from lung adenocarcinoma pleural effusions: molecular characterization and tumor engraftment","volume":"6","author":"Di Napoli","year":"2011","journal-title":"PLoS One"},{"key":"24","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1038\/sj.bjc.6603851","article-title":"Valproic acid (VPA) in patients with refractory advanced cancer: a dose escalating phase I clinical trial","volume":"97","author":"Jager","year":"2007","journal-title":"Br J Cancer"},{"key":"25","doi-asserted-by":"crossref","first-page":"3189","DOI":"10.1158\/1078-0432.CCR-08-2999","article-title":"A phase I, pharmacokinetic and pharmacodynamic study on vorinostat in combination with 5-fluorouracil, leucovorin, and oxaliplatin in patients with refractory colorectal cancer","volume":"15","author":"Egorin","year":"2009","journal-title":"Clin Cancer Res"},{"key":"26","doi-asserted-by":"publisher","first-page":"31","DOI":"10.18632\/oncotarget.430","article-title":"A combination of a ribonucleotide reductase inhibitor and histone deacetylase inhibitors downregulates EGFR and triggers BIM-dependent apoptosis in head and neck cancer","volume":"3","author":"Schneider","year":"2012","journal-title":"Oncotarget"},{"key":"27","doi-asserted-by":"crossref","first-page":"1795","DOI":"10.1111\/jcmm.12583","article-title":"Intensified antineoplastic effect by combining an HDAC-inhibitor, an mTOR-inhibitor and low dosed interferon alpha in prostate cancer cells","volume":"19","author":"Blaheta","year":"2015","journal-title":"J Cell Mol Med"},{"key":"28","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/j.canlet.2011.07.015","article-title":"Histone deacetylase inhibitor valproic acid suppresses the growth and increases the androgen responsiveness of prostate cancer cells","volume":"311","author":"Lin","year":"2011","journal-title":"Cancer Lett"},{"key":"29","doi-asserted-by":"crossref","first-page":"2717","DOI":"10.1002\/ijc.29320","article-title":"The combination of irreversible EGFR TKIs and SAHA induces apoptosis and autophagy-mediated cell death to overcome acquired resistance in EGFR T790M-mutated lung cancer","volume":"136","author":"Kim","year":"2015","journal-title":"Int J Cancer"},{"key":"30","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1186\/1476-4598-13-105","article-title":"Targeting of erbB3 receptor to overcome resistance in cancer treatment","volume":"13","author":"Liu","year":"2014","journal-title":"Mol Cancer"},{"key":"31","doi-asserted-by":"crossref","first-page":"929","DOI":"10.1083\/jcb.200109033","article-title":"c-erbB-3: a nuclear protein in mammary epithelial cells","volume":"157","author":"Grunt","year":"2002","journal-title":"J Cell Biol"},{"key":"32","doi-asserted-by":"publisher","first-page":"10222","DOI":"10.18632\/oncotarget.2655","article-title":"Regulation of ERBB3\/HER3 signaling in cancer","volume":"5","author":"An","year":"2014","journal-title":"Oncotarget"},{"key":"33","doi-asserted-by":"crossref","first-page":"2849","DOI":"10.1096\/fj.06-7925com","article-title":"The E3 ligase Aip4\/Itch ubiquitinates and targets ErbB-4 for degradation","volume":"21","author":"Alimandi","year":"2007","journal-title":"FASEB J"},{"key":"34","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1007\/s00418-008-0401-3","article-title":"Endocytic downregulation of ErbB receptors: mechanisms and relevance in cancer","volume":"129","author":"van Deurs","year":"2008","journal-title":"Histochem Cell Biol"},{"key":"35","doi-asserted-by":"crossref","first-page":"2180","DOI":"10.1128\/MCB.01245-06","article-title":"Neuregulin-induced ErbB3 downregulation is mediated by a protein stability cascade involving the E3 ubiquitin ligase Nrdp1","volume":"27","author":"Carraway","year":"2007","journal-title":"Mol Cell Biol"},{"key":"36","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1093\/annonc\/mdn703","article-title":"ErbB-3 expression is associated with E-cadherin and their coexpression restores response to gefitinib in non-small-cell lung cancer (NSCLC)","volume":"20","author":"Hirsch","year":"2009","journal-title":"Ann Oncol"},{"key":"37","doi-asserted-by":"crossref","first-page":"1230","DOI":"10.1016\/j.bbrc.2015.06.090","article-title":"Trichostatin A suppresses lung adenocarcinoma development in Grg1 overexpressing transgenic mice","volume":"463","author":"Lobe","year":"2015","journal-title":"Biochem Biophys Res Commun"},{"key":"38","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1158\/1078-0432.CCR-14-1150","article-title":"DUSP1 expression induced by HDAC1 inhibition mediates gefitinib sensitivity in non-small cell lung cancers","volume":"21","author":"Chen","year":"2015","journal-title":"Clin Cancer Res"},{"key":"39","doi-asserted-by":"crossref","first-page":"925","DOI":"10.1158\/1535-7163.MCT-12-1045","article-title":"Potential advantages of CUDC-101, a multitargeted HDAC, EGFR, and HER2 inhibitor, in treating drug resistance and preventing cancer cell migration and invasion","volume":"12","author":"Lai","year":"2013","journal-title":"Mol Cancer Ther"},{"key":"40","doi-asserted-by":"crossref","first-page":"944","DOI":"10.1158\/0008-5472.CAN-05-1988","article-title":"Restoring E-cadherin expression increases sensitivity to epidermal growth factor receptor inhibitors in lung cancer cell lines","volume":"66","author":"Franklin","year":"2006","journal-title":"Cancer Res"},{"key":"41","doi-asserted-by":"publisher","first-page":"12481","DOI":"10.18632\/oncotarget.3489","article-title":"Induction of c-Cbl contributes to anti-cancer effects of HDAC inhibitor in lung cancer","volume":"6","author":"Chen","year":"2015","journal-title":"Oncotarget"},{"key":"42","first-page":"79","article-title":"Human epidermal growth factor receptor 3 (HER3) blockade with U3-1287\/AMG888 enhances the efficacy of radiation therapy in lung and head and neck carcinoma","volume":"16","author":"Wheeler","year":"2013","journal-title":"Discov Med"},{"key":"43","doi-asserted-by":"crossref","first-page":"823","DOI":"10.4161\/epi.21141","article-title":"Epigenetics: judge, jury and executioner of stem cell fate","volume":"7","author":"Lunyak","year":"2012","journal-title":"Epigenetics"},{"key":"44","doi-asserted-by":"crossref","first-page":"6520","DOI":"10.1158\/1078-0432.CCR-13-0877","article-title":"The histone deacetylase inhibitor abexinostat induces cancer stem cells differentiation in breast cancer with low Xist expression","volume":"19","author":"Charafe-Jauffret","year":"2013","journal-title":"Clin Cancer Res"},{"key":"45","doi-asserted-by":"crossref","first-page":"1720","DOI":"10.1002\/jcp.24300","article-title":"EMT markers in lung adenocarcinoma pleural effusion spheroid cells","volume":"228","author":"Mancini","year":"2013","journal-title":"J Cell Physiol"},{"key":"46","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1158\/1078-0432.CCR-05-1671","article-title":"Synergistic antitumor activity of epidermal growth factor receptor tyrosine kinase inhibitor gefitinib and IFN-alpha in head and neck cancer cellsand","volume":"12","author":"Budillon","year":"2006","journal-title":"Clin Cancer Res"},{"key":"47","doi-asserted-by":"crossref","first-page":"8403","DOI":"10.1158\/0008-5472.CAN-09-2146","article-title":"HDAC inhibitor SNDX-275 induces apoptosis in erbB2-overexpressing breast cancer cells via down-regulation of erbB3 expression","volume":"69","author":"Liu","year":"2009","journal-title":"Cancer Res"},{"key":"48","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1016\/j.canlet.2011.03.019","article-title":"HDAC inhibitor SNDX-275 enhances efficacy of trastuzumab in erbB2-overexpressing breast cancer cells and exhibits potential to overcome trastuzumab resistance","volume":"307","author":"Liu","year":"2011","journal-title":"Cancer Lett"},{"key":"49","doi-asserted-by":"crossref","first-page":"2485","DOI":"10.1158\/0008-5472.CAN-09-3145","article-title":"An ErbB3 antibody, MM-121, is active in cancers with ligand-dependent activation","volume":"70","author":"Nielsen","year":"2010","journal-title":"Cancer Res"},{"key":"50","first-page":"ra31","article-title":"Therapeutically targeting ErbB3: a key node in ligand-induced activation of the ErbB receptor-PI3K axis","volume":"2","author":"West","year":"2009","journal-title":"Sci Signal"},{"key":"51","doi-asserted-by":"publisher","first-page":"744","DOI":"10.18632\/oncotarget.550","article-title":"The promise of anti-ErbB3 monoclonals as new cancer therapeutics","volume":"3","author":"Ciliberto","year":"2012","journal-title":"Oncotarget"},{"key":"52","doi-asserted-by":"crossref","first-page":"824","DOI":"10.1158\/0008-5472.CAN-12-1611","article-title":"Dual targeting of EGFR and HER3 with MEHD7945A overcomes acquired resistance to EGFR inhibitors and radiation","volume":"73","author":"Harari","year":"2013","journal-title":"Cancer Res"},{"key":"53","doi-asserted-by":"crossref","first-page":"582","DOI":"10.1158\/1535-7163.MCT-11-0820","article-title":"Antitumor activity of a novel bispecific antibody that targets the ErbB2\/ErbB3 oncogenic unit and inhibits heregulin-induced activation of ErbB3","volume":"11","author":"Wallace","year":"2012","journal-title":"Mol Cancer Ther"},{"key":"54","doi-asserted-by":"crossref","first-page":"1107","DOI":"10.1093\/jnci\/82.13.1107","article-title":"New colorimetric cytotoxicity assay for anticancer-drug screening","volume":"82","author":"Boyd","year":"1990","journal-title":"J Natl Cancer Inst"},{"key":"55","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1006\/meth.2001.1262","article-title":"Analysis of relative gene expression data using real-time quantitative PCR and the 2(\u2212Delta Delta C(T)) Method","volume":"25","author":"Schmittgen","year":"2001","journal-title":"Methods"}],"container-title":["Oncotarget"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.oncotarget.com\/lookup\/doi\/10.18632\/oncotarget.7195","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,5,11]],"date-time":"2020-05-11T18:29:53Z","timestamp":1589221793000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.oncotarget.com\/lookup\/doi\/10.18632\/oncotarget.7195"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,2,4]]},"references-count":55,"journal-issue":{"issue":"15","published-print":{"date-parts":[[2016,4,12]]}},"alternative-id":["7195","26862736"],"URL":"https:\/\/doi.org\/10.18632\/oncotarget.7195","relation":{},"ISSN":["1949-2553"],"issn-type":[{"value":"1949-2553","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,2,4]]}}}